Slate Medicines
slatemedicines.com
Actively hiring
Health Care
Neurology & CNS Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$140M
2 rounds on record
Latest round
$130M
Series A · Feb 2026 · 7 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 14
New executive Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer · slatemedicines.com
Jul 16
Board appointment Slate Medicines Appoints Mark W. Hahn to Board of Directors · YahooFinance
May 18
New executive Slate Medicines Appoints John Umstead as Chief Financial Officer · slatemedicines.com
Feb 17
Raised a round Venture round $10M · SEC Form D
2024
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Feb 2026 | $130M | — | Pulse 2.0 |
| Venture round | Feb 2026 | $10M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Slate Medicines, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Sara PachecoExecutive OfficerSEC Form D
Neil BuckleyExecutive Officer, DirectorSEC Form D
Gregory OakesExecutive OfficerSEC Form D
Similar startupsby what they do, their industry and backers
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Biomia rationally engineers nature-inspired novel small molecule therapeutics to treat CNS disorders.
Boldly advancing the next generation of medicines for Alzheimer’s Disease and Related Dementias.
Damona Pharmaceuticals is developing precision neuromedicines to reverse cognitive deficits associated with brain disorders.associated with…
Our mission is to give people with migraine a better life. As a pioneer in the field of medical devices, Salvia BioElectronics is…
Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience…
Overview
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache disorders.
News
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
RALEIGH, N.C. - Slate Medicines Inc. ("Slate"), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache dis
Read more
Report
Slate Medicines Announces First Participant Dosed in Phase 1 Study Evaluating SLTE-1009
Phase 1 single- and multiple-ascending dose study in healthy volunteers evaluating the pharmacokinetics and safety of SLTE-1009; Topline safety and pharmacokinetic data expected mid-2027 RALEIGH, N.C. - Slate Medicines Inc., ("Slate"), a clinical stage bi
Read more
Report
Fulcrum Therapeutics And Slate Medicines To Merge With $245 Million Financing And Estimated $270 Million Fulcrum Dividend
Fulcrum Therapeutics and Slate Medicines have entered into a definitive all-stock merger agreement that will create a Nasdaq-listed biotechnology company focused on next-generation migraine treatments and backed by an oversubscribed $245 million private p
Read more
Report
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate's lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclon
Read more
Report
Pro access
Upgrade to see all 15 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Sara Pacheco
Executive Officer
Neil Buckley
Executive Officer, Director
Gregory Oakes
Executive Officer
Tim Lohoff
Director
Cindy Xiong
Director
Andrew Levin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ
50-200 est. staff